New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
07:25 EDTINO, INOInovio Pharma management to meet with JMP Securities
Meeting to be held in San Francisco on February 5 hosted by JMP Securities.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
05:19 EDTINOInovio partners with GeneOne Life Science for MERS immunotherapy development
Inovio Pharmaceuticals announced it will advance its DNA vaccine for MERS, or Middle East Respiratory Syndrome, into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science. MERS is a respiratory disease caused by a coronavirus, which is related to the severe acute respiratory syndrome, or SARS, virus. Currently, MERS carries a 40% death rate; there is no vaccine or effective treatment for this virus. Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio's DNA-based MERS vaccine. The companies are currently conducting pre-IND activities and plan to start the clinical study before year end. GeneOne will conduct and fund the clinical study in return for milestone-based co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize this product. In preclinical tests, INO-4500 showed robust and durable immune responses. Animals vaccinated with INO-4500 generated strong neutralizing antibodies and robust CD8+ T cells to MERS antigens. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
May 22, 2015
16:10 EDTINOInovio files $250M mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use